Inclusion Criteria:  Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) Diagnosed with type 2 diabetes mellitus The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study Male or female, age above or equal to 20 years at the time of signing informed consent Available glycated haemoglobin (HbA1c) value greater than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (Visit 1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (Visit 1) if in line with local clinical practice Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than 14 days  Exclusion Criteria:  Previous participation in this study. Participation is defined as having given informed consent in this study Treatment with any investigational drug within 30 days prior to enrolment into the study Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation